It Seems Calithera Biosciences Incorporated (NASDAQ:CALA) Will Go Down. Just Reported More Shorted Shares

September 17, 2017 - By Clifton Ray

 It Seems Calithera Biosciences Incorporated (NASDAQ:CALA) Will Go Down. Just Reported More Shorted Shares

Investors sentiment increased to 1.2 in Q4 2016. Its up 0.44, from 0.76 in 2016Q3. It improved, as 9 investors sold Calithera Biosciences Inc shares while 6 reduced holdings. 4 funds opened positions while 14 raised stakes. 5.98 million shares or 0.90% more from 5.92 million shares in 2016Q3 were reported.
Blackrock Management Ltd accumulated 2,467 shares or 0% of the stock. Fmr Limited Co stated it has 386,598 shares. The New York-based First Eagle Investment Mgmt Ltd has invested 0% in Calithera Biosciences Inc (NASDAQ:CALA). Jacobs Levy Equity Mgmt, a New Jersey-based fund reported 22,065 shares. California Employees Retirement System reported 14,100 shares. Tfs Capital Ltd accumulated 28,408 shares. Wells Fargo Co Mn stated it has 8,520 shares. Oxford Asset Mgmt invested 0.01% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Morgan Stanley reported 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Bridgeway Management has 158,100 shares. Vanguard Inc accumulated 0% or 462,878 shares. Blackrock Advsr Ltd Liability Company holds 0% or 2,540 shares in its portfolio. Millennium Ltd Llc has invested 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA). Susquehanna Intll Grp Llp has 74,569 shares for 0% of their portfolio. Goldman Sachs Grp Inc Incorporated stated it has 0% of its portfolio in Calithera Biosciences Inc (NASDAQ:CALA).

The stock of Calithera Biosciences Incorporated (NASDAQ:CALA) registered an increase of 0.03% in short interest. CALA’s total short interest was 2.92M shares in September as published by FINRA. Its up 0.03% from 2.92 million shares, reported previously. With 386,200 shares average volume, it will take short sellers 8 days to cover their CALA’s short positions. The short interest to Calithera Biosciences Incorporated’s float is 22.25%.

The stock decreased 0.66% or $0.1 on September 15, reaching $15.05. About 1.01M shares traded or 114.09% up from the average. Calithera Biosciences Inc (NASDAQ:CALA) has risen 278.82% since September 17, 2016 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $533.92 million. The Firm focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It currently has negative earnings. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Calithera Biosciences Inc (NASDAQ:CALA) Ratings Coverage

Among 4 analysts covering Calithera Biosciences (NASDAQ:CALA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Calithera Biosciences had 8 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, January 5. The firm has “Neutral” rating by Citigroup given on Tuesday, January 24. The company was initiated on Tuesday, October 25 by Citigroup. Citigroup initiated it with “Buy” rating and $11 target in Friday, July 24 report. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. H.C. Wainwright maintained Calithera Biosciences Inc (NASDAQ:CALA) rating on Tuesday, March 28. H.C. Wainwright has “Buy” rating and $14 target. The rating was maintained by H.C. Wainwright on Monday, June 12 with “Buy”.

More notable recent Calithera Biosciences Inc (NASDAQ:CALA) news were published by: Globenewswire.com which released: “Incyte and Calithera Biosciences Announce Global Collaboration to Develop and …” on January 30, 2017, also Globenewswire.com with their article: “Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent …” published on August 08, 2017, Globenewswire.com published: “Calithera Biosciences to Participate in the Citi 12th Annual Biotech …” on August 30, 2017. More interesting news about Calithera Biosciences Inc (NASDAQ:CALA) were released by: Globenewswire.com and their article: “Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care …” published on March 01, 2017 as well as Fool.com‘s news article titled: “Here’s Why Calithera Biosciences Stock Gained as Much as 16.4% Today” with publication date: May 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.